IMAB
I-MABIMAB
IMAB
About: I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).
Employees: 32
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
45% more call options, than puts
Call options by funds: $16K | Put options by funds: $11K
4% more funds holding
Funds holding: 28 [Q4 2024] → 29 (+1) [Q1 2025]
0% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 5
1.57% less ownership
Funds ownership: 6.4% [Q4 2024] → 4.83% (-1.57%) [Q1 2025]
27% less capital invested
Capital invested by funds: $10.1M [Q4 2024] → $7.41M (-$2.72M) [Q1 2025]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$4
61%
upside
Avg. target
$5.50
121%
upside
High target
$7
181%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
Needham Gil Blum | 61%upside $4 | Buy Reiterated | 4 Apr 2025 |
HC Wainwright & Co. Andrew Fein | 181%upside $7 | Buy Maintained | 4 Apr 2025 |
Financial journalist opinion
Based on 3 articles about IMAB published over the past 30 days
Positive
Zacks Investment Research
4 days ago
I-Mab Sponsored ADR (IMAB)'s Technical Outlook is Bright After Key Golden Cross
I-Mab Sponsored ADR (IMAB) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, IMAB's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.
Positive
Zacks Investment Research
1 week ago
I-Mab Sponsored ADR (IMAB) is a Great Momentum Stock: Should You Buy?
Does I-Mab Sponsored ADR (IMAB) have what it takes to be a top stock pick for momentum investors? Let's find out.
Neutral
GlobeNewsWire
3 weeks ago
I-Mab to Present at Jefferies Global Healthcare Conference
ROCKVILLE, Md., May 20, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the “Company”), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that I-Mab's management team will participate in the Jefferies Global Healthcare Conference, being held June 3-5, 2025. During the event, I-Mab's management will discuss clinical progress on its lead program, givastomig.
Negative
Zacks Investment Research
2 months ago
After Plunging -20.33% in 4 Weeks, Here's Why the Trend Might Reverse for IMab (IMAB)
The heavy selling pressure might have exhausted for IMab (IMAB) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Negative
Zacks Investment Research
2 months ago
After Plunging -19.7% in 4 Weeks, Here's Why the Trend Might Reverse for IMab (IMAB)
The heavy selling pressure might have exhausted for IMab (IMAB) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Neutral
GlobeNewsWire
2 months ago
I-Mab Announces Receipt Of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
ROCKVILLE, Md., March 21, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (“I-Mab” or the “Company”), announced today that on March 19, 2025 it received a written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company is not in compliance with the $1.00 minimum bid price requirement under the Nasdaq Listing Rules (the “Listing Rules”). Based on the closing bid price of the Company's listed securities for the period from February 3, 2025 to March 18, 2025, the Company has not met the minimum bid price requirement set forth in Listing Rule 5450(a)(1) during that period. The Notice is only a notification of deficiency and has no immediate effect on the listing of the Company's American Depositary Shares (“ADS”). The Company's ADSs will continue to trade on the Nasdaq Global Market at this time. The Company's receipt of the Notice does not impact the Company's business, operations or reporting requirements with the U.S. Securities and Exchange Commission.
Neutral
GlobeNewsWire
3 months ago
I-Mab Announces Accelerated Givastomig Phase 1b Study Progress
ROCKVILLE, Md., March 07, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the “Company”), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that enrollment has been completed ahead of schedule in the first dose expansion cohort in the Phase 1b givastomig combination study, with continued momentum in the second dose expansion cohort. The Phase 1b study is evaluating givastomig, a potential best-in-class, Claudin 18.2 (CLDN18.2) x 4-1BB bispecific antibody, targeting CLDN18.2-expressing tumor cells for the treatment of gastric cancer in the first-line (1L) setting. The Phase 1b program includes a dose escalation study (n=17) and a dose expansion study (n=40). Enrollment in the dose escalation study is complete, and topline data are expected in the second half of 2025.
Neutral
GlobeNewsWire
3 months ago
I-Mab to Participate in Leerink Partners Global Healthcare Conference
ROCKVILLE, Md., Feb. 18, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the “Company”), a US-based, global biotech company, exclusively focused on the development of precision immune-oncology agents for the treatment of cancer, today announced that members of I-Mab's management will participate in one-on-one meetings at the Leerink Partners Global Healthcare Conference in Miami, Florida on Tuesday and Wednesday, March 11-12, 2025.
Neutral
GlobeNewsWire
4 months ago
I-Mab to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference
ROCKVILLE, Md., Feb. 04, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that I-Mab's management team will participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference, being held virtually, on February 11-12, 2025.
Neutral
PRNewsWire
5 months ago
I-Mab Announces Open Market Purchases of Company American Depositary Shares by Board Member
Chairman of the Board, Wei Fu, informed the Company of his intent to purchase up to $2,000,000 of the Company's American Depository Shares (ADSs) ROCKVILLE, Md. , Jan. 8, 2025 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced the Company has been informed that Wei Fu, the Chairman of the Board, intends to purchase up to $2,000,000 of the Company's ADSs in open market transactions.
Charts implemented using Lightweight Charts™